Aptevo Therapeutics Inc. has entered into a $60 million equity line of credit (ELOC) agreement with Yorkville Advisors Global, LP. This financing facility provides Aptevo with flexible access to capital, allowing the company to raise funds incrementally and at its discretion under market-based conditions. The ELOC, which carries minimal fees and no warrants, is intended to support ongoing clinical development, advance preclinical programs, and fund general corporate purposes. Together with existing cash on hand, the fully leveraged facility is expected to extend Aptevo's funding runway into 2029, enabling the achievement of key clinical and preclinical milestones. The company retains full discretion over the use of the facility and is not required to draw on it.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1125926) on January 09, 2026, and is solely responsible for the information contained therein.